オプションチェーンは、Grace Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Grace Therapeuticsの市場センチメントを評価します。.

Grace Therapeutics (NASDAQ:GRCE) 株価情報, オプションチェーン

Grace Therapeutics

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Grace Therapeutics Inc

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock is trading lower on Tuesday after BYD Auto announced plans to include self-driving technology <a href="https://www.benzinga.com//node/43620317">in its cars</a>.
The Details: According to <a href="https://www.cnbc.com/2025/02/11/byd-rolls-out-driver-assist-tech-for-evs-with-deepseeks-ai-help.html">CNBC</a>, BYD is working with DeepSeek to develop and launch its &#8220;DiPilot&#8221; assisted driving system. The technology will be available across its vehicle lineup, including a model priced at 69,800 yuan ($9,555).
The company mentioned that DeepSeek&#8217;s artificial intelligence model will be included in at least the more advanced version of the driver-assistance program. Driver assistance programs typically combine software, artificial intelligence and sensors to control the vehicle and reduce the need for human intervention.
BYD&#8217;s founder and chairman, Wang Chuanfu, stated during a China-focused launch event live streamed late Monday that advanced smart driving will soon be a standard safety feature, much like seatbelts and airbags.
BYD originally had a different view on integrating self-driving technology. In March 2023, the company told investors that determining liability for autonomous vehicles was challenging, but it also recognized the potential for improved safety in self-driving cars.
Nomura analysts said in a Tuesday note that BYD&#8217;s move to include advanced driver-assistance features in a vehicle priced under 70,000 yuan likely makes it the first automaker in China to do so.
NIO shares may be trading lower after BYD&#8217;s announcement, as investors may view it as a competitive threat, especially with the technology being included in more affordable models.
See Also: <a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/43623929/wall-streets-most-accurate-analysts-spotlight-on-3-utilities-stocks-delivering-high-dividend-yields-6">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields</a>
NIO Price Action: At the time of publication, NIO stock is trading 4.50% lower at $4.13, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: via Shutterstock

News

Movers

What's Going On With NIO Shares Tuesday?

Keybanc analyst Jackson Ader upgrades Monday.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from Sector Weight to Overweight and announces $420 price target.

Upgrades

Price Target

Analyst Ratings

MNDY

Keybanc Upgrades Monday.Com to Overweight, Announces $420 Price Target

Stifel analyst Brian Chin maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Buy and lowers the price target from $250 to $235.

AMAT

Stifel Maintains Buy on Applied Mat, Lowers Price Target to $235

Dominari Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMH#NASDAQ">DOMH</a>) shares are trading higher Tuesday, adding to gains after rallying more than 90% to start the week. Here&#8217;s a look at <a href="https://www.benzinga.com/pressreleases/25/02/ac43622373/dominari-holdings-inc-announces-13-5-million-registered-direct-and-private-placement-offerings-pr">what&#8217;s going on</a>. 
What To Know: Dominari Holdings shares surged 91% on Monday despite a lack of company-specific news. The stock appears to be getting some attention across social media platforms as retail investors highlight the company&#8217;s investments. 
According to a filing showing holdings as of Sept. 31, 2024, Dominari maintains investments in several popular companies including Anduril, xAI, Epic Games, Discord and more. 
On Tuesday, Dominari shares were halted in early trading for pending news. Shares surged after the company announced that Donald Trump Jr. and Eric Trump have joined the company&#8217;s board. 
&#8220;We are thrilled to welcome Don Jr. and Eric as advisors to our team. They have each achieved significant success across a wide range of industries and bring invaluable leadership and strategic insight that we believe will be highly beneficial for our firm,&#8221; said Kyle Wool, CEO of Dominari Securities.
&#8220;Their&nbsp;guidance&nbsp;is expected to be instrumental as we continue to seek attractive investment opportunities, particularly in the rapidly evolving AI and Data Center sector.&#8221;
See Also: <a href="https://www.benzinga.com/markets/equities/25/02/43622400/sam-altman-says-elon-musks-97b-bid-for-openai-is-a-move-to-slow-down-a-competitor">Sam Altman Says Elon Musk&#8217;s $97B Bid For OpenAI Is A Move To &#8216;Slow Down A Competitor&#8217;</a>
Trump Jr. and Eric Trump also participated in a private placement that was announced Tuesday morning. Dominari said it entered into definitive securities purchase agreements with certain investors for approximately 1.44 million shares of its common stock. 
Series A warrants to purchase up to 1.44 million shares and series B warrants to purchase up to 1.44 million shares were offered in a registered direct offering at a combined purchase price of $3.47 per share.
In a concurrent private placement, Dominari also agreed to issue and sell approximately 2.44 million shares of common stock, Series A warrants to purchase up to 2.44 million shares of common stock and Series B warrants to purchase up to 2.44 million shares of common stock at the same purchase price as in the registered direct offering.&nbsp;
Additionally, Dominari announced that its board declared a special cash dividend of&nbsp;$4 million&nbsp;for stockholders of record as of the close of business on Feb. 24.
Dominari anticipates gross proceeds of approximately $13.5 million. The company intends to use net proceeds for working capital and general corporate purposes, as well as for the payment of the special cash dividend. 
DOMH Price Action: <a href="http://benzinga.com/quote/domh">Dominari Holdings shares</a> closed Monday up 91.3% at $6.16. The stock was up 37.3% Tuesday morning, trading at $8.47 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43622684/shopify-q4-earnings-31-revenue-surge-free-cash-flow-growth-gmv-hits-94-5-billion">Shopify Q4 Earnings: 31% Revenue Surge, Free Cash Flow Growth, GMV Hits $94.5 Billion</a></li>
</ul>
Photo: Shutterstock.

DOMH

Dominari Holdings Stock Is Soaring: What's Going On?

Crypto analyst Miles Deutscher argues that the <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43032768/bitcoins-4-year-cycle-is-breaking-and-thats-a-good-thing-industry-expert-says">four-year crypto cycle is obsolete</a>, replaced by a new market structure shaped by Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) ETFs and macroeconomic trends.
What Happened: In a <a href="https://x.com/milesdeutscher/status/1889002881736744993">post</a> on X on Monday, Deutscher stated that the traditional 4-year crypto cycle is no longer relevant due to two major shifts. 
First, the Bitcoin halving has less impact, as each successive supply reduction becomes less significant in influencing price action.
Second, the introduction of Bitcoin ETFs have altered demand, where instead of profits rotating into altcoins as in past cycles, ETF-driven capital stays within Bitcoin, disrupting the traditional BTC wealth effect. 
This has skipped Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and major altcoins, fueling direct speculation in smaller on-chain assets instead.
With these shifts, macro factors now play a larger role in shaping crypto's price action, rather than predictable halving-driven cycles.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43602728/why-bitcoin-outperformed-solana-ethereum-in-last-weeks-flash-crash">Why Bitcoin Outperformed Solana, Ethereum In Last Week&#8217;s Flash Crash</a>
What's Next: Instead of waiting for an altseason, Deutscher urges traders to focus on short-term opportunities within emerging market narratives.
A more effective strategy in 2025 involves a balanced portfolio: 50% in long-term high conviction plays like Bitcoin, Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) and 50% in stablecoins or active trades, with a focus on compounding small wins over time. 
By staying nimble and consistently taking profits, investors can capitalize on the evolving market structure while minimizing risk.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43505966/bitcoin-struggling-but-perfect-storm-will-take-it-to-500000-ethereum-to-20000-trader-predicts">Bitcoin Struggling But &#8216;Perfect Storm&#8217; Will Take It To $500,000, Ethereum To $20,000, Trader Predicts</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$SOL

The Bitcoin 4-Year Cycle Is Dead, Analyst Says: 'Adapt Or Die'

On Tuesday, Leidos Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) reported fourth-quarter fiscal 2024 revenue growth of 10% year-over-year to $4.37 billion, beating the <a href="https://www.benzinga.com/pressreleases/25/02/n43617405/leidos-posts-strong-fourth-quarter-and-fiscal-year-2024-results" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $4.13 billion</a>. Demand across all customer segments, especially for managed health services, drove the increase. 
The defense, aviation, information technology and biomedical research, the company&#8217;s adjusted EPS was $2.37, up 19% year-over-year, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst consensus estimate of $2.27</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43533402/roblox-q4-earnings-topline-and-user-growth-miss-estimates-fy25-outlook-lags-stock-slides" rel="noreferrer noopener">Roblox Q4 Earnings: Topline And User Growth Miss Estimates, FY25 Outlook Lags, Stock Slides</a>
Adjusted net income was $316 million for the quarter, up 14% year-over-year.
Adjusted EBITDA was $508 million, up 12% year over year. The margin of 11.6% increased from 11.4% a year ago.&nbsp;
Net bookings totaled $7.6 billion for the quarter, representing a book-to-bill ratio 1.7.&nbsp;As a result, the backlog at the end of the year was $43.6 billion, of which $8.4 billion was funded.&nbsp;
Leidos held $943 million in cash and equivalents as of January&nbsp;3, 2025.
CEO Tom Bell said 2024 results came at or above the high end of its guidance range across all metrics, with the fourth quarter especially strong in revenue growth and business development. Also, its 2024 performance propelled the company beyond the three-year targets established at its 2021 Investor Day.
Outlook:&nbsp;Leidos expects fiscal 2025 revenue of $16.9 billion–$17.3 billion. The analyst <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus stands&nbsp;at $16.98 billion</a>.
The company expects its fiscal 2024 adjusted EPS of $10.35–$10.75 versus the&nbsp;$10.58 consensus.
Leidos Holdings stock surged 25% in the last 12 months. However, at least three Wall Street firms cut <a target="_blank" href="https://www.benzinga.com/quote/LDOS/analyst-ratings" rel="noreferrer noopener">their price target</a> on the stock since December 2024, including two downgrades of ratings by Goldman Sachs and TD Cowen.
Price Action: LDOS stock is up 0.16% at $143.00 premarket at last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43535385/thomson-reuters-q4-earnings-beats-estimates-boosts-dividend-10-ceo-highlights-strategic-growth" target="_blank" rel="noreferrer noopener">Thomson Reuters Q4 Earnings: Beats Estimates, Boosts Dividend 10%, CEO Highlights Strategic Growth</a></li>
</ul>
Photo: Shutterstock

Earnings

LDOS

Leidos Q4 Earnings: $7.6 Billion In Net Bookings, CEO Highlights Business Momentum And 2025 Outlook

Economists and betting markets are leaning toward a mild January inflation report, fueling investor hopes that price pressures are cooling and the Federal Reserve could stay on track <a href="https://www.benzinga.com/topic/interest-rates">for interest rate cuts. </a>
The headline Consumer Price Index is expected to hold steady at 2.9% year-over-year, according to median economist forecasts tracked by TradingEconomics. On a monthly basis, inflation is projected to rise by 0.3%, slightly cooling from December's 0.4% gain. 
Core inflation, which excludes volatile food and energy prices, is anticipated to ease from 3.2% to 3.1% year-over-year, marking the first annual decline in core CPI since July 2024. However, on a monthly basis, core inflation is expected to rise 0.3%, slightly above December's 0.2% increase.
Ahead of the January inflation report, markets are fully pricing in just one rate cut by the end of the year, while the probability of two reductions by December 2025 stands at about 50% as per the CME FedWatch tool.
<h3 class="wp-block-heading">What Do Betting Markets Expect?</h3>
Kalshi, a CFTC-regulated betting market platform, reflects similar expectations, with odds slightly favoring a 2.9% CPI reading.
The probability of inflation exceeding 2.9% stands at 2-to-1 odds, while an even surprisingly hotter print above 3.0% would yield a $53 return on a $10 wager.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXCPIYOY-25JAN?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
Meanwhile, betting markets assign a 62% probability to core CPI exceeding the 3.1% economist consensus, reflecting concerns about persistent underlying price pressures.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXCPICOREYOY-25JAN?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
Also Read: <a href="https://www.benzinga.com/markets/equities/25/02/43622400/sam-altman-says-elon-musks-97b-bid-for-openai-is-a-move-to-slow-down-a-competitor">Sam Altman Says Elon Musk&#8217;s $97B Bid For OpenAI Is A Move To &#8216;Slow Down A Competitor&#8217;</a>
<h3 class="wp-block-heading">Wall Street Weighs Key Inflation Drivers</h3>
Economists from major banks are analyzing key components of the January inflation report, with a particular focus on goods prices, shelter costs, and services inflation. 
Bank of America economist Aditya Bhave expects core goods prices to rise, largely due to higher new and used car prices, which are forecasted to increase by 0.3% and 2.0% month-over-month, respectively. Yet, outside the auto sector, core goods prices are generally expected to decline amid improving supply conditions.
Shelter inflation, which has been a persistent driver of price pressures, is also under scrutiny. Bhave projects core services inflation to tick up to 0.4% month-over-month in January. 
He highlighted that the Bureau of Labor Statistics has been increasing the weight of single-family detached homes within the Owners' Equivalent Rent (OER) calculation each January, while reducing the weight of multifamily units. Other service components are also expected to show modest acceleration.
&#8220;We remain comfortable with our forecast that the Fed cutting cycle is over. Inflation is stuck above target, with risks skewed to the upside, activity is strong, and the labor market appears to have stabilized around full employment,&#8221; Bhave wrote in a Tuesday report. 
Goldman Sachs economist Jessica Rindels anticipates a slightly hotter-than-expected inflation print, forecasting a 0.34% increase in core CPI for January, compared to the 0.3% consensus estimate. 
She expects headline CPI to rise 0.36% month-over-month, driven by a 0.4% increase in food prices and a 0.6% jump in energy prices. 
Looking ahead, Goldman Sachs expects &#8220;further disinflation in the pipeline over the next year from rebalancing in the auto, housing rental, and labor markets, but an offset from an escalation in tariff policy.&#8221;&nbsp;
<h3 class="wp-block-heading">What This Means For The Fed</h3>
Michael Rosner, managing director at Raymond James, suggests that while the report will influence the Fed's thinking, markets may still be six to eight months away from the first rate cut. 
Unless economic conditions change significantly, he indicates the central bank will stick to its &#8220;wait and see&#8221; approach.
Ed Yardeni, president of Yardeni Research, highlights a seasonal factor that could push inflation higher in January. 
&#8220;Businesses tend to raise prices at the beginning of the year; that could result in&nbsp;January&nbsp;CPI&nbsp;and PPI&nbsp;releases&nbsp;(Wed and Thu)&nbsp;that are&nbsp;hotter&nbsp;than&nbsp;expected&nbsp;even though both are seasonally adjusted,&#8221; Yardeni said. 
He added that some Federal Reserve officials have recently expressed concerns that tariffs could disrupt progress toward the Fed's 2% inflation target.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43608052/traders-rethink-interest-rate-path-as-inflation-concerns-resume-feds-rate-cutting-cycle-is-over-economist-says">Traders Rethink Interest-Rate Path As Inflation Concerns Resume: &#8216;Fed&#8217;s Rate-Cutting Cycle Is Over,&#8217; Economist Says</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Econ #s

Economics

Federal Reserve

Economists, Betting Markets Predict Benign January Inflation: What Could Go Wrong This Time?

Susquehanna analyst Christopher Rolland maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Positive and lowers the price target from $70 to $60.

Susquehanna Maintains Positive on ON Semiconductor, Lowers Price Target to $60

Gaia Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) core streaming video subscription business is "compelling," with unique content and stable margins, according to Roth Capital Partners.
The Gaia Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5804744e846faa000106a9e0/george-kelly">Analyst George Kelly</a> initiated coverage of Gaia with a Buy rating and a price target of $10.
The Gaia Thesis: The company's streaming business now has 850,000 subscribers and a more predictable margin structure, Kelly said in the initiation note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
"Content focuses on alternative healing, spirituality, ancient civilization, etc., and is mostly produced in-house, allowing for material cost efficiencies," he added.
Among the documentaries viewers can stream on Gaia, include &#8220;Heal&#8221; with Deepak Chopra and Marianne Williamson, as well as &#8220;Sensitive: The Untold Story,&#8221; featuring singer Alanis Morissette.
Gaia introduced price hikes in the fourth quarter, which will roll out through the member base this year. This will provide "a material tailwind," the analyst stated. "We also see potential for another increase in 2026," he further wrote.
The company is using AI to enter new geographies and offer curation and chat, Kelly said. "We expect growth to accelerate from pricing and a host of soon-to-launch initiatives," he wrote.
Price Action: Shares of Gaia had risen by 5.00% to $5.25 at the time of publication on Tuesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/insights/earnings/25/02/43493881/earnings-breakdown-reservoir-media-q3">Earnings Breakdown: Reservoir Media Q3</a><a href="https://www.benzinga.com/25/01/42953261/nvidia-broadcom-and-marvell-positioned-for-growth-as-ai-demand-drives-semiconductor-momentum"></a></li>
</ul>
Image: Shutterstock

Analyst Color

Initiation

GAIA

This Video Streaming Company Has Stable Margins, Prospects To Accelerate Growth: Analyst

Finalizing scale-up production phase
Engaging with Contract Research Organizations to complete the technical dossier
Clinical trials expected to complete in late 2025 or early 2026
Potential classification as a Class III medical device
Product launch expected in the first or second quarter of 2026
Further updates on progress to follow in the coming months

Biotech

General

COSM

Cosmos Health Enters Final Development Phase Of CCX0722 Weight Management Solution

Susquehanna analyst Christopher Rolland maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Positive and raises the price target from $70 to $75.

LSCC

Susquehanna Maintains Positive on Lattice Semiconductor, Raises Price Target to $75

WIIM

ARVN

Arvinas shares are trading lower after the company reported worse-than-expected Q4 sales results.

Keybanc analyst John Vinh maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Overweight and raises the price target from $70 to $75.

Keybanc Maintains Overweight on Lattice Semiconductor, Raises Price Target to $75

Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) announced that it will integrate its Inspection and Reconditioning Center capabilities into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43618819/carvana-announces-auction-irc-megasite-integration-in-indianapolis" rel="noreferrer noopener">existing ADESA Indianapolis wholesale auction site.</a>
The new &#8220;Megasite&#8221; will combine Carvana&#8217;s digital and in-lane auction operations with reconditioning services, boosting the company&#8217;s production capacity and offering serviceS to retail and wholesale customers in the Indianapolis area.
The transition is expected to create approximately 200 new jobs locally.
The ADESA Indianapolis site in Plainfield spans over 100 acres and includes nearly 12,000 parking spaces, providing infrastructure for Carvana&#8217;s expanded operations.
The site has been a significant player in the wholesale automotive market, and Carvana&#8217;s integration of IRC capabilities will add another layer to its offerings.
Also Read:<a target="_blank" href="https://www.benzinga.com/25/02/43618537/bp-q3-results-lower-revenue-rising-debt-but-175-billion-buyback-and-dividend-hike-impress" rel="noreferrer noopener"> BP Q4 Results: Lower Revenue, Rising Debt, CEO Pledges Fundamental Strategy Shift And More</a>
Carvana&#8217;s move to expand its reconditioning capacity through this integration enhances its nationwide inventory, offering local customers quicker access to vehicles with potential same-day delivery.
Additionally, wholesale customers will benefit from enhanced auction operations, supported by Carvana&#8217;s CARLI software.
Mike Caggiano, Executive Vice President of Operations at ADESA, emphasized the integration&#8217;s potential to improve services for retail and wholesale customers while also creating new job opportunities. This development represents a significant step in Carvana&#8217;s efforts to strengthen its operational footprint and improve delivery efficiency in the region.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, CVNA stock has gained over 387% in the past year. Investors can gain exposure to the stock via&nbsp;Invesco Dorsey Wright Consumer Cyclicals Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEZ#NASDAQ">PEZ</a>).
Price Action: CVNA shares are trading higher by 0.55% to $269.29 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43614105/activist-investor-elliott-builds-25-billion-stake-in-phillips-66-pressures-for-midstream-spinoff-report" target="_blank" rel="noreferrer noopener">Activist Investor Elliott Builds $2.5 Billion Stake In Phillips 66, Pressures For Midstream Spinoff: Report</a></li>
</ul>
Photo via Shutterstock.

Equities

Markets

CVNA

PowerShares Dynamicnsumer Discretionary Sector Portfolio

What's Going On With Carvana Stock Today?

RGNX

Regenxbio shares are trading lower after Goldman Sachs downgraded the stock from Buy to Neutral and cut its price target from $38 to $14.

Kinross Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGC#NYSE">KGC</a>) has outperformed the market over the past 5 years by 5.19% on an annualized basis producing an average annual return of 17.57%. Currently, Kinross Gold has a market capitalization of $14.69 billion. 
Buying $1000 In KGC: If an investor had bought $1000 of KGC stock 5 years ago, it would be worth $2,366.34 today based on a price of $11.95 for KGC at the time of writing.
<h3>Kinross Gold's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739286930_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $1000 Invested In Kinross Gold 5 Years Ago Would Be Worth Today

Few speeches stand the test of time, but Steve Jobs' <a href="https://youtu.be/UF8uR6Z6KLc?si=5m6XEuBXuhMilRXI">2005 Stanford University commencement address </a>isn't just remembered—it's studied, quoted, and dissected like scripture for the modern entrepreneur. It wasn't a formulaic "go chase your dreams" pep talk. Instead, Jobs used his own life—dropping out of college, getting fired from Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), facing death—to remind graduates that life is unpredictable, and the only real mistake is not following your own path.
<h2 class="wp-block-heading">The Speech That Defined a Generation</h2>
When <a href="https://www.benzinga.com/tech/25/02/43578844/bill-gates-says-steve-jobs-once-told-him-i-wish-youd-take-acid-that-would-enhance-microsofts-product-design-more-i-envy-those-skills-im-not-in-his-league">Steve Jobs took the stage</a> at Stanford, he wasn't a struggling entrepreneur. He was Steve Freaking Jobs—the visionary behind Apple, Pixar, and the Macintosh, standing at the peak of his career. Yet, instead of a victory lap, he delivered a brutally honest message:
"Your time is limited, so don't waste it living someone else's life."
Don't Miss:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a></li>
</ul>
He wasn't talking about reckless ambition or quitting your job tomorrow. He was talking about trusting yourself—even when life doesn't go according to plan.
<h2 class="wp-block-heading">Lesson #1: "You Can't Connect the Dots Looking Forward"</h2>
Jobs dropped out of Reed College after six months. No plan, no roadmap—just instinct. He floated from class to class, crashing on friends' dorm floors, collecting Coke bottle deposits for food, and walking seven miles for a good meal at a Hare Krishna temple.
One class he "randomly" took? Calligraphy.
It seemed useless at the time. But 10 years later, that knowledge helped Jobs design the first Macintosh, making it the first personal computer with beautiful typography. If he hadn't dropped out, computers might still look like government spreadsheets.
"You have to trust that the dots will somehow connect in your future," he said.&nbsp;
The takeaway? You don't always see where you're headed—but looking back, every choice matters.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
<h2 class="wp-block-heading">Lesson #2: "Sometimes Life Hits You in the Head with a Brick. Don't Lose Faith."</h2>
At 30, Jobs was at the top of the world—running Apple, the company he co-founded. Then, Apple fired him. His own board, the one he built, kicked him out of his own company.
Public humiliation. Industry outcast. Game over, right? Not for Jobs.
"Getting fired from Apple was the best thing that could have ever happened to me," he said.&nbsp;
Without Apple, he was free. He launched NeXT and Pixar, two companies that would define modern animation and <a href="https://www.benzinga.com/startups/25/01/42858542/steve-jobs-said-hiring-seasoned-professionals-at-apple-didnt-work-because-most-of-them-were-bozos-who-didnt-know-how-to-do-anything">Apple's comeback</a>. When Apple eventually bought NeXT, he returned as CEO—this time, to build the iPhone.
The lesson? Failure isn't the end. It's a reset.
Trending: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
<h2 class="wp-block-heading">Lesson #3: "Death is Life's Change Agent."</h2>
Then, Jobs dropped a reality check: one day, you will die.
A year before the speech, Jobs was diagnosed with pancreatic cancer and given three to six months to live. He spent the day preparing for the end—only to find out his cancer was rare and curable.
But the wake-up call stuck with him.
"Remembering that you are going to die is the best way I know to avoid the trap of thinking you have something to lose," he said.&nbsp;
When death is inevitable, why live by someone else's expectations? Why play it safe?
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Final Words: "Stay Hungry. Stay Foolish."</h2>
Jobs ended with a quote from The Whole Earth Catalog, a 1970s book that inspired him. The words?
"Stay hungry. Stay foolish."
In other words: Don't settle. Keep pushing. Be curious. Take risks.
That was Jobs' real message. Not just for Stanford graduates, but for anyone afraid of making the wrong move. Because in the end, the only real failure is not trusting yourself enough to try.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

AAPL

Steve Jobs Delivered Powerful Life Message In His Most Memorable Speech: 'Your Time is Limited So Don't Waste It Living Someone Else's Life'

In the current session, the stock is trading at $69.86, after a 1.19% increase. Over the past month, Western Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) stock increased by 11.44%, and in the past year, by 24.68%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1739286908_0.png" alt="Past Year Chart" />

<h3>Comparing Western Digital P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Western Digital has a lower P/E than the aggregate P/E of 33.87 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1739286908_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Western Digital

Canaccord Genuity analyst Austin Moeller maintains Spire Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) with a Buy and raises the price target from $18 to $24.

SPIR

Canaccord Genuity Maintains Buy on Spire Global, Raises Price Target to $24

AIOT

PowerFleet shares are trading higher after Northland Capital Markets raised its price target on the stock from $10 to $11.

Grace Therapeutics GAAP EPS of -$0.30 beats by $0.06

Acasti Pharma, Inc. ( ($GRCE) ) has released its Q2 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors...

Grace Therapeutics Reports Steady Progress and Financials

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Grace Therapeutics (GRCE – Research Report). The compa...

Craig-Hallum Reaffirms Their Buy Rating on Grace Therapeutics (GRCE)

Grace Therapeutics (GRCE) will be participating in the mid-year clinical meeting of the American Society of Health-System Pharmacists to be held De...

Grace Therapeutics to exhibit at ASHP Conference

Grace therapeutics announces private placement financing of $30 million

Grace Therapeutics (GRCE) announced that its Phase 3 STRIVE-ON safety trial met its primary endpoint and provides evidence of clinical benefit when...

Grace Therapeutics announces results from Phase 3 STRIVE-ON trial

Grace Therapeutics meets main goal in late stage trial for its aneurysmal SAH treatment

GRCE

Health Care

Press Releases

Grace Therapeutics to Host Virtual KOL Event on GTx-104 in aneurysmal Subarachnoid Hemorrhage on November 20, 2024

Grace Therapeutics Announces Second Fiscal Quarter 2025  Financial Results, Provides Business Update

Grace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference

Grace Therapeutics to Participate in Upcoming Investor Events January 2025

Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH

Financing

Grace Therapeutics Announces Private Placement Financing of up to $30 Million

ACST

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

AN2 Therapeutics

CalciMedica

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Context Therapeutics

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Dare Bioscience

Durect

Impact BioMedical

IGC Pharma

Opus Genetics

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Lexaria Bioscience

Marinus Pharmaceuticals, Inc. - Common Stock

Marinus Pharma

NRX Pharmaceuticals

OptiNose

Pulmatrix

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

SCYNEXIS

Traws Pharma

Verrica Pharmaceuticals Inc. - Common Stock

Comments

Grace Therapeutics

Grace Therapeutics (GRCE) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル